Penulis: Ahearn, Thomas U, Anton-Culver, Hoda, Arndt, Volker, Augustinsson, Annelie, Auvinen, Päivi K, Becher, Heiko, Beckmann, Matthias W, Behrens, Sabine, Blomqvist, Carl, Bojesen, Stig E, Bolla, Manjeet K, Brenner, Hermann, Briceno, Ignacio, Brucker, Sara Y, Camp, Nicola J, Campa, Daniele, Canzian, Federico, Castelao, Jose E, Chanock, Stephen J, Choi, Ji-Yeob, Clarke, Christine L, Collaborators, for the NBCS, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Dunning, Alison M, Dwek, Miriam, Dörk, Thilo, Easton, Douglas F, Eccles, Diana M, Egan, Kathleen M, Evans, D Gareth, Fasching, Peter A, Flyger, Henrik, Freeman, Laura E Beane, Gago-Dominguez, Manuela, Gapstur, Susan M, García-Sáenz, José A, Gaudet, Mia M, Giles, Graham G, Grip, Mervi, Guénel, Pascal, Haiman, Christopher A, Hall, Per, Hamann, Ute, Han, Sileny N, Hart, Steven N, Hartman, Mikael, Heyworth, Jane S, Hoppe, Reiner, Hopper, John L, Hunter, David J, Håkansson, Niclas, Investigators, for the ABCTB, Ito, Hidemi, Jager, Agnes, Jakimovska, Milena, Jakubowska, Anna, Janni, Wolfgang, Jung, Audrey Y, Kaaks, Rudolf, Kang, Daehee, Kapoor, Pooja Middha, Keeman, Renske, Kitahara, Cari M, Koutros, Stella, Kraft, Peter, Kristensen, Vessela N, Lacey, James V, Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Lindblom, Annika, Lubiński, Jan, Lush, Michael, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Mariapun, Shivaani, Matsuo, Keitaro, Mavroudis, Dimitrios, Milne, Roger L, Morra, Anna, Muranen, Taru A, Newman, William G, Noh, Dong-Young, Nordestgaard, Børge G, Obi, Nadia, Olshan, Andrew F, Olsson, Håkan, Park-Simon, Tjoung-Won, Petridis, Christos, Pharoah, Paul DP, Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rashid, Muhammad U, Rennert, Gad, Rennert, Hedy S, Rhenius, Valerie
Diterbitkan: 1 April 2021
Dalam analisis gabungan yang melibatkan 121,435 wanita yang didiagnosis dengan kanser payudara invasif daripada 67 kajian (16,890 kematian, 8,554 kes khusus kanser payudara dalam tempoh 10 tahun), aktiviti fizikal tinggi berbanding rendah dikaitkan dengan nisbah risiko sebanyak 0.43 (95% CI 0.21-0.86) bagi kadar kematian keseluruhan dalam tempoh 10 tahun. Tiada bukti menunjukkan hubungan yang tidak seragam berdasarkan status ER atau subtipe seperti intrinsik diperhatikan (P adj > 0.30), yang menunjukkan bahawa manfaat tersebut terpakai kepada semua subtipe kanser payudara yang dikaji.